REGENXBIO Inc. (RGNX)
REGENXBIO Statistics
Share Statistics
REGENXBIO has 50.12M shares outstanding. The number of shares has increased by 1.69% in one year.
| Shares Outstanding | 50.12M |
| Shares Change (YoY) | 1.69% |
| Shares Change (QoQ) | 1.09% |
| Owned by Institutions (%) | 82.82% |
| Shares Floating | 45.21M |
| Failed to Deliver (FTD) Shares | 248 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 5.25M, so 10.48% of the outstanding shares have been sold short.
| Short Interest | 5.25M |
| Short % of Shares Out | 10.48% |
| Short % of Float | 12.75% |
| Short Ratio (days to cover) | 4.54 |
Valuation Ratios
The PE ratio is -1.69 and the forward PE ratio is -8.99. REGENXBIO's PEG ratio is 0.07.
| PE Ratio | -1.69 |
| Forward PE | -8.99 |
| PS Ratio | 4.59 |
| Forward PS | 0.7 |
| PB Ratio | 1.47 |
| P/FCF Ratio | -2.18 |
| PEG Ratio | 0.07 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for REGENXBIO.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.69 |
| Quick Ratio | 2.69 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | -0.41 |
| Debt / FCF | -0.47 |
| Interest Coverage | -18.43 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $236.06K |
| Profits Per Employee | $-643.35K |
| Employee Count | 353 |
| Asset Turnover | 0.18 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -40.69% in the last 52 weeks. The beta is 1.26, so REGENXBIO's price volatility has been higher than the market average.
| Beta | 1.26 |
| 52-Week Price Change | -40.69% |
| 50-Day Moving Average | 7.18 |
| 200-Day Moving Average | 9.37 |
| Relative Strength Index (RSI) | 70.85 |
| Average Volume (20 Days) | 946.48K |
Income Statement
In the last 12 months, REGENXBIO had revenue of 83.33M and earned -227.1M in profits. Earnings per share was -4.59.
| Revenue | 83.33M |
| Gross Profit | 49.76M |
| Operating Income | -233.35M |
| Net Income | -227.1M |
| EBITDA | -198.23M |
| EBIT | -214.44M |
| Earnings Per Share (EPS) | -4.59 |
Balance Sheet
The company has 57.53M in cash and 82.03M in debt, giving a net cash position of -24.51M.
| Cash & Cash Equivalents | 57.53M |
| Total Debt | 82.03M |
| Net Cash | -24.51M |
| Retained Earnings | -932.15M |
| Total Assets | 465.99M |
| Working Capital | 174.81M |
Cash Flow
In the last 12 months, operating cash flow was -173.13M and capital expenditures -2.44M, giving a free cash flow of -175.56M.
| Operating Cash Flow | -173.13M |
| Capital Expenditures | -2.44M |
| Free Cash Flow | -175.56M |
| FCF Per Share | -3.55 |
Margins
Gross margin is 59.72%, with operating and profit margins of -280.03% and -272.54%.
| Gross Margin | 59.72% |
| Operating Margin | -280.03% |
| Pretax Margin | -272.54% |
| Profit Margin | -272.54% |
| EBITDA Margin | -237.89% |
| EBIT Margin | -280.03% |
| FCF Margin | -210.69% |
Dividends & Yields
RGNX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RGNX is $30, which is 204% higher than the current price. The consensus rating is "Buy".
| Price Target | $30 |
| Price Target Difference | 204% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | -2.36 |
| Piotroski F-Score | 4 |